Funding for this research was provided by:
Chief Scientist Office (PDF/15/07)
Wellcome Trust (201492/Z/16/Z)
Text and Data Mining valid from 2019-01-17
Received: 7 September 2018
Accepted: 27 November 2018
First Online: 17 January 2019
: The data that support the findings of this study are available from the SCI-Diabetes database and the Electronic Data Research and Innovation Service of the Information Services Division of the NHS National Services Scotland, but restrictions apply to the availability of these data, which were used under licence for the current study and so are not publicly available. Data are, however, available with permission of the NHS Scotland Public Benefit and Privacy Panel for Health and Social Care.
: HMC reports grants, personal fees and non-financial support from AstraZeneca, Boehringer Ingelheim, Bayer, Eli Lilly, Novartis Pharmaceuticals, Regeneron, Pfizer, Roche Pharmaceuticals, Sanofi-aventis, Sanofi and Novo Nordisk outside the submitted work. NS reports grants and personal fees from Boehringer Ingelheim, Janssen, Novo Nordisk, Eli Lilly, Amgen, AstraZeneca and Sanofi outside the submitted work. No other potential conflicts of interest relevant to this article were reported.